H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT [Yahoo! Finance]
Acrivon Therapeutics (NASDAQ:ACRV) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference [Yahoo! Finance]